Millions of Americans take a daily multivitamin expecting it to add years to their lives. Two major lines of federal research now say that expectation is wrong. A large cohort analysis published in JAMA Network Open found no reduction in mortality risk among regular multivitamin users, and the COSMOS randomized clinical trial of approximately 21,442 older adults reached the same conclusion after years of follow-up. Yet a separate meta-analysis of 12 randomized controlled trials found that multivitamin-multimineral supplements did lower blood pressure, with the clearest effects appearing in people who already had hypertension or chronic disease. The split verdict raises a pointed question: if the pills do not extend life, what exactly are they doing inside the body, and for whom does that matter?
Why the mortality finding changes the multivitamin conversation
The tension here is straightforward. Roughly half of U.S. adults report taking a dietary supplement, and multivitamins are the most popular category. The implicit promise behind that habit is longevity, or at least protection against serious disease. An analysis led by researchers at the National Cancer Institute, described in a recent federal summary, used observational data from a large U.S. cohort and found that daily multivitamin use did not lower the risk of death from any cause. With extended follow-up and tens of thousands of participants, the study carried statistical power that many earlier supplement trials lacked.
That observational result did not stand alone. The COSMOS randomized clinical trial, registered as NCT02422745, tested a widely used multivitamin (Centrum Silver) against placebo in approximately 21,442 participants and found no effect on all-cause mortality. Because COSMOS was randomized rather than observational, it could rule out many of the confounding factors that weaken cohort analyses, such as the tendency of health-conscious people to take supplements and also exercise more or smoke less. Two different study designs, two different research teams, and the same bottom line: daily multivitamins did not help people live longer.
The U.S. Preventive Services Task Force reached a compatible conclusion in its own systematic evidence review, which examined vitamin, mineral, and multivitamin supplementation for the primary prevention of cardiovascular disease and cancer. That USPSTF review found insufficient proof that multivitamins prevent either condition in the general adult population. Taken together, the three bodies of evidence form a consistent picture: for people without a diagnosed nutrient deficiency, a daily pill does not buy extra time. Public health researchers at the National Cancer Institute’s Division of Cancer Epidemiology have emphasized that diet quality, physical activity, and avoidance of tobacco remain the pillars of long-term risk reduction.
Blood pressure dropped in people who needed help most
The story does not end with mortality. A meta-analysis of 12 randomized controlled trials, published in the journal Nutrients, examined the effects of multivitamin and multimineral supplementation specifically on blood pressure. The pooled results showed a reduction in blood pressure among supplement users, and subgroup analysis revealed that the effect was concentrated among participants who had hypertension or other chronic conditions at baseline. Normotensive adults saw little or no change. That pattern suggests the supplements are not acting as a universal tonic but are correcting something specific in people whose cardiovascular systems are already under strain.
One plausible explanation is that the mineral content, not the vitamin content, is doing the heavy lifting. Potassium and magnesium both have well-established roles in vascular tone and sodium balance. Many adults with hypertension consume diets low in both minerals. A multivitamin-multimineral formulation that includes meaningful doses of potassium and magnesium could produce a modest systolic drop in those individuals without affecting people whose mineral intake is already adequate. If that hypothesis holds, the observed blood-pressure benefit would be a mineral-replacement effect rather than a vitamin effect, and it could be replicated more cheaply with targeted mineral supplements.
Testing that idea would not require a new trial. The 12 RCTs pooled in the Nutrients paper, accessible as a meta-analysis on PubMed Central, contain detailed information on supplement composition and dosing. A re-analysis stratifying results by the potassium and magnesium content of each formulation could clarify whether minerals alone account for the blood-pressure signal. No such re-analysis has been published, leaving open the possibility that other components, such as B vitamins involved in endothelial function, might also contribute.
Gaps in the data that still need closing
Several pieces of evidence remain missing. The COSMOS trial collected baseline medication and dietary intake data, as described in its design and baseline characteristics paper, but those variables have not been cross-tabulated with blood-pressure outcomes in any published analysis. Without that cross-tabulation, it is impossible to know whether COSMOS participants who were already taking antihypertensive drugs experienced a different supplement effect than those who were not. If multivitamins slightly lower blood pressure only in people whose hypertension is untreated or poorly controlled, the clinical relevance would be very different than if the effect appears even on top of standard therapy.
The USPSTF evidence review, meanwhile, did not isolate blood-pressure effects by baseline hypertension status. Its scope covered cardiovascular disease and cancer prevention broadly, which means the specific subgroup finding from the Nutrients meta-analysis has not been validated by the federal task force’s own pooled estimates. That gap matters because USPSTF recommendations carry direct weight in clinical practice and insurance coverage decisions. If future guideline updates were to acknowledge a small but consistent blood-pressure benefit in high-risk groups, clinicians might feel more comfortable recommending certain formulations as adjuncts to lifestyle change and medication.
Long-term mortality data for the blood-pressure trials are also sparse. Most of the 12 RCTs in the meta-analysis were relatively short, focusing on surrogate endpoints such as systolic and diastolic pressure rather than hard outcomes like stroke, myocardial infarction, or cardiovascular death. It is biologically plausible that a sustained reduction in blood pressure, even of a few millimeters of mercury, could translate into fewer events over time. But without extended follow-up, that link remains hypothetical. COSMOS, with its longer horizon, could in theory help bridge this gap if investigators were to analyze whether any subgroup with elevated blood pressure at baseline derived cardiovascular benefit despite the neutral overall mortality result.
Another unresolved issue is formulation diversity. “Multivitamin” is not a single product but a broad category with widely varying doses and ingredient lists. Some preparations contain only vitamins; others add minerals in amounts that approach or exceed recommended daily intakes. The JAMA Network Open cohort study and the COSMOS trial both evaluated commonly used formulations, but they cannot speak for every product on the market. The Nutrients meta-analysis likewise pooled trials that differed in composition. Until researchers systematically compare high-mineral and low-mineral blends head-to-head, any attempt to generalize about “multivitamins” as a class will remain imprecise.
What this means for patients and clinicians
For generally healthy adults, the emerging consensus is clear: taking a daily multivitamin is unlikely to extend life or meaningfully reduce the risk of cancer and cardiovascular disease. Those outcomes are driven more by diet, activity, and other behaviors than by supplemental pills. Clinicians can reassure patients that skipping a multivitamin, in the absence of a known deficiency or specific medical indication, is unlikely to shorten their lifespan.
For people with hypertension or chronic disease, the picture is more nuanced. The blood-pressure signal seen in randomized trials suggests that certain multivitamin-multimineral formulations may offer a modest benefit, particularly when diets are low in potassium and magnesium. However, that potential upside should be weighed against cost, pill burden, and the lack of definitive evidence linking supplementation to fewer heart attacks or strokes. In most cases, improving dietary quality-emphasizing fruits, vegetables, legumes, and whole grains-will provide the same minerals along with fiber and other cardioprotective compounds.
Future research can sharpen these trade-offs. Participant-level re-analyses of existing trials, better characterization of supplement formulations, and subgroup reporting by baseline blood-pressure status would all help clarify who, if anyone, truly benefits from a multivitamin. Until then, the safest interpretation of current evidence is modest: multivitamins are not longevity drugs, and any cardiovascular advantages they offer are likely small, targeted, and best viewed as complements-not substitutes-to proven lifestyle and pharmacologic therapies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
